XOMA Corporation (XOMA)
Q2 2012 Earnings Call
August 7, 2012 4:30 pm ET
Ashleigh Barreto – Investor Relations
John W. Varian – Chief Executive Officer
Paul D. Rubin – Senior Vice President, Research and Development and Chief Medical Officer
Fred Kurland – Vice President-Finance and Chief Financial Officer
Adnan Butt – RBC Capital Markets
Matthew Kaplan – Ladenburg Thalmann & Co.
Liana Moussatos – Wedbush Securities
Thomas Yip – MLV & Co.
Whitney Ijem – Canaccord Genuity Inc.
Joseph Pantginis – Roth Capital Partners
Good afternoon, ladies and gentlemen, and welcome to XOMA Corporation’s Second Quarter 2012 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call may be recorded.
I would now like to turn the call over to your host for today, Ashleigh Barreto, Investor Relations at XOMA. You may proceed.
Thank you, operator. Good afternoon and welcome to XOMA Corporation’s Second quarter 2012 financial results and corporate update conference call. On our call today are John Varian, Chief Executive Officer; Dr. Paul Rubin, Senior Vice President, Research and Development and Chief Medical Officer; and Fred Kurland, Chief Financial Officer.
Certain statements made during this call including but limited to statement related to anticipated timing of initiation and completion of clinical trials, anticipated size of clinical trials, continued sales of approved products, regulatory approval of unapproved product candidates and anticipated restructuring charges, sufficiency of our cash resources, and anticipated levels of cash utilization or otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.